1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Vital Signs - Healthcare News - The Analyst's Perspective - June 2014

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogen's Eloctate, Qiagen's acquisition of Primera Dx, Roche's acquisition of Genia Technologies, Cue's at-home connected lab test, and the Credihealth Teen Clinic.

LIFE SCIENCES
US FDA Approves Biogen’s Hemophilia A Drug Eloctate
Source: Reuters, June 6, 2014

The US Food and Drug Administration (FDA) announced on Friday, June 6, 2014, that it approved Biogen Idec Inc’s
long-lasting hemophilia A drug, Eloctate, adding it to the company’s portfolio of drugs for non-malignant blood
disorders. Eloctate is the first recombinant clotting factor VIII therapy with prolonged circulation in the body,
which eliminates at least one dosing every week for prophylactic use in both children and adults.
The Analyst’s Perspective by Steven Atkinson, Senior Industry Analyst,
Life Sciences, North America

Biogen’s product line continues to grow, especially in the blood disorder area. Eloctate is the second hemophilia
drug approved by the FDA in the past three months, beating the likes of Novo Nordisk and Baxter to market.
Alprolix for hemophilia A was approved in March 2014. These two FDA approvals are the results of Biogen’s
fruitful collaboration with Sobi (Swedish Orphan Biovitrum).

Eloctate was used as a prophylactic in a pediatric study; kids experienced a median annual bleeding rate of 2.0.
Close to half of the subjects had no bleeding episodes to report, and 96% of the children who did experience an
episode said their bleeding was controlled after one or two doses.

Hemophilia A and B combined market population is more than 160, 000 worldwide, with a total combined market
revenue of $7 billion annually. Eloctate and Alprolix are estimated to have combined revenues of over $1.5 billion
by 2019. As an analyst, I would deem this collaboration to be a fairly successful deal if those estimates are met.
With the addition of these recent approvals to Biogen’s current portfolio of multiple sclerosis drugs, Avonex,
Tecfidera and Tysabri, Biogen can possibly tout two blockbuster drugs in the coming years.

Qiagen Buys Primera Dx and Expands its Companion Diagnostics Portfolio
Source: Genomeweb, June 5, 2014
Qiagen, a global giant in the molecular diagnostics segment, recently announced that it acquired PrimeraDx, a
molecular diagnostics start-up in the Boston area. PrimeraDx is primarily known for its flagship product, Modaplex
(also known as the ICEPlex), a multi-analytic and multi-modal testing system. Modaplex is the first of its kind to
use multiple assays for a single sample. It enables the analysis of multiple biomarkers in a single reaction.
The Analyst’s Perspective by Aishwarya Vivekanandan, Industry Analysts,

Life Sciences, North America
Molecular diagnostics is the fastest growing segment in the overall IVD market. The double-digit growth is
primarily contributed by the expanding companion diagnostics market. Large pharmaceutical companies have long
since moved away from the one-size-fits-all model in drug development, realizing the importance of diagnostics
in personalized therapy. Many of these pharmaceutical companies incorporate and partner with global majors
like Qiagen to monitor their developed drugs to encourage personalized medication with patients. This is one of
the underlying reasons that led to the acquisition of PrimeraDx by Qiagen. There were a few other compelling
reasons why Qiagen made the strategic move of acquiring PrimeraDx:

Table Of Contents

Vital Signs - Healthcare News - The Analyst's Perspective - June 2014
LIFE SCIENCES
US FDA Approves Biogen's Hemophilia A Drug Eloctate.. 2
Qiagen Buys Primera Dx and Expands its Companion Diagnostics Portfolio... 2
Roche Acquires Sequencing Technology Startup Genia Technologies
for $350M, Pending Milestones. 3
Cue to Offer at-Home, Smartphone - Connected Lab Tests... 4
Credihealth Teens Clinic: An Online Clinic for Teenagers.. 6

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.